Rx or OTC for generic desloratadine
This article was originally published in The Tan Sheet
Executive Summary
Generic pharmaceutical firm Mylan may market desloratadine tablets (5 mg) in the U.S. beginning in July 2012 in direct competition with Schering-Plough's Clarinex allergy medication, according to a patent litigation settlement announced April 8. Pending FDA's approval of Pittsburgh-based Mylan's abbreviated new drug application, the firm can market the tablets as Rx or OTC depending on the status at the time for Clarinex, which is considered a likely switch candidate (1"The Tan Sheet" Feb. 4, 2008, p. 5). Sales of desloratadine tablets (5 mg) reached $284 million in the U.S. during 2008, according to IMS Health
You may also be interested in...
Morgan Stanley Analysts Handicap Potential Switches In Near Future
With the potential to cash in on up to $10 billion in branded sales in the next five years, a number of prescription drugs are positioned to break into the OTC market by 2012, Morgan Stanley analysts say
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.